GlassScriptPhysician profile
Kathryn Lyle
NPI 1649710054
$6,507.22
in general payments reported to CMS, 2019-2025
12 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 97% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $459 · 2023: $3,160 · 2024: $580 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,979 · Food and Beverage: $1,101 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $920 · Honoraria: $560 · Travel and Lodging: $483 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,979.12 |
| Food and Beverage | $1,100.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $920.00 |
| Honoraria | $560.00 |
| Travel and Lodging | $482.81 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $2,415.65 | 2023 | Elahere |
| Corcept Therapeutics | $1,096.77 | 2025 | |
| Glaxosmithkline, LLC. | $948.11 | 2021-2025 | Jemperli |
| Merck Sharp & Dohme LLC | $575.36 | 2022-2025 | Lynparza |
| Pfizer INC. | $560.00 | 2024 | |
| Clovis Oncology, INC. | $256.06 | 2021-2022 | |
| Eisai INC. | $183.96 | 2021-2025 | |
| Seagen INC. | $156.61 | 2022-2023 | Tivdak |
| E.R. Squibb & Sons, L.L.C. | $99.10 | 2021 | |
| Myriad Genetic Laboratories, INC. | $94.21 | 2023 | Precisetumor |
| Bayer Healthcare Pharmaceuticals INC. | $84.39 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $37.00 | 2024-2025 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.